zandile has type 2 diabetes
  •  

Diabetes

Our ambition

Novo Nordisk has been a leader in diabetes care since 1923 and continues to pioneer the development of novel treatments for this serious condition.

We are constantly striving to improve the lives of people with diabetes by finding better methods of diabetes treatment and prevention.

Our partnering focus - therapeutic compounds

Insulin and GLP-1 receptor peptide-agonists:

  • Insulins and GLP-1s with novel therapeutic properties
    • Optimised for oral delivery
    • Modified duration of action
    • Improved side-effect profile

Therapeutic proteins and peptides affecting:

  • Glucose regulation
    • Without inducing hypoglycaemia and/or
    • Without inducing weight gain and/or
    • With anti-obesity effects and/or
    • With anti-hyperlipidaemia/anti-atherosclerosis effects
  • Insulin secretion
  • Insulin resistance
  • Beta-cell mass
  • Obesity
  • Diabetes late complications
  • Inflammation related to diabetes and obesity
  • Prevention/progression of diabetes

Our partnering focus - technologies

Protein and peptide technologies:

  • Expression
  • Modification
  • Production

Formulation and drug delivery technologies for proteins and peptides:

  • Liquid
  • Oral
  • Sustained/triggered release

Read more about Diabetes Research Unit

Contact us

For further information please contact Diabetes Innovation Sourcing



  •  

Download partnering for innovation bruchure

  •  
  •  

Where to meet us

We are attending events all over the world to meet with new potential partners.

Event calendar

  •  
  •  

Contact us

For further information about our partnering focus in diabetes please contact:
Diabetes Innovation Sourcing

  •  
  •  

R&D pipeline

Read more about our diabetes pipeline

  •